

Changing Preferences: An Experiment and Estimation of Market-Incentive Effects on Altruism

Undral Byambadalai, Boston University

Ching-to Albert Ma, Boston University

Daniel Wiesen, University of Cologne

Preferences

- **Always assumed exogenous**
 - as in **Arrow-Debreu** for example
- **Shaped by things economists don't quite understand**
 - Except perhaps until recently?
 - **Decision theory, behavioral economics?**
- **Markets and incentives**
- **Usually studied under GIVEN preferences**
- **Can markets, incentives change preferences?**
 - **Compare with: Can culture and upbringing change preferences?**

Challenges

- Behaviors observed; not preferences
- Behaviors change due to interaction between preferences and markets and incentives
- How to refute hypothesis that markets and incentives change preferences?
- Resolution:
 - Structural model
 - Game-theoretical model of preferences, markets, incentives
 - Experimental data
 - Structural nonparametric estimation of preferences

Typical experiments

- **Bartling, Weber, and Yao 2015, Quarterly Journal of Economics, “Do Markets Erode Social Responsibility”**
 - **Buyers; sellers, third parties; production externalities to harm third parties**
 - **Do sellers choose more costly production to avoid externality?**
 - **Do buyers pay more to get clean products?**
 - **Posted-price markets**
- **Falk and Szech 2013, Science, “Morals and Markets”**
 - **“Mouse paradigm”**

Preferences

- **Common buzzwords: altruism, prosocial behavior, intrinsic motivation, honesty, other-regarding, etc.**
- **Identifying changes more likely if preferences are not all about profit or self-interest**
- **Medical context:**
 - **Ken Arrow 1963, American Economic Review, “The Welfare Economics of Medical Care”**
 - **His behavior is supposed to be governed by a concern for the customer’s welfare which would not be expected of a salesman**
 - **Arrow’s “His” refers to “The Doctor”**
 - **Altruism**

Experiment and results

- **Framing: health care quality**
- **Incentives: price, cost, patient benefit**
- **Markets: Monopoly, Duopoly, Quadropoly**

- **Preferences changed by incentives**
- **Preferences changed by markets**
 - **Markets have stronger effects than incentives**
 - **Subjects become less altruistic; preferences exhibit different variances**

Theory: market and demand

- Monopoly; all patients must go to one physician
- Duopoly: two physicians, qualities q_1, q_2

- Logistic market shares:

$$\frac{\exp(bq_1)}{\exp(bq_1) + \exp(bq')} \equiv S(q_1; q')$$

- Quadropoly: four physicians, qualities $q_1, q_2, q_3,$ and q_4

- Logistic market shares:

$$\frac{\exp(bq_1)}{\sum_{i=1}^4 \exp(bq_i)} \quad \dots \quad \dots \quad \frac{\exp(bq_4)}{\sum_{i=1}^4 \exp(bq_i)}$$

- Demand elasticities: duopoly $<$ quadropoly

Theory: incentives and preferences

- Patient benefit b
- Price p , fixed revenue
- Cost parameter c ; unit cost increasing and convex in quality q
 - Incentive configuration: (p, c, b)
- Utility: $\alpha b q + U(p - cq^2)$ per patient
- Altruism: α_i for physician i
 - distribution of α_i in each incentive configuration and in each market

Monopoly optimal qualities

- **Quality:** $\max_q \alpha b q + U(p - cq^2)$
- **Simple tradeoff**
- **Benchmark**
 - **Giving up profit to benefit patient**

Duopoly Bayes Nash Equilibria

- Let α be distributed on $[\underline{\alpha}, \bar{\alpha}]$, distribution F
- Strategy: $q : [\underline{\alpha}, \bar{\alpha}] \rightarrow [0, 10]$
- Given rival's strategy q' , player i 's payoff:

$$[\alpha_1 b q_1 + U(p - c q_1^2)] \times \int_{\underline{\alpha}}^{\bar{\alpha}} \left[\frac{100 \exp(b q_1)}{\exp(b q_1) + \exp(b q'(x))} \right] dF(x)$$

- Symmetric Bayes-Nash Equilibrium:

$$q^*(\alpha) = \operatorname{argmax}_q [\alpha b q + U(p - c q^2)] \times \int_{\underline{\alpha}}^{\bar{\alpha}} 100 S(q_1; q^*(x)) dF(x)$$

Bayes Nash and monotonicity

Equilibrium strategy $q^* : [\underline{\alpha}, \bar{\alpha}] \rightarrow [0, 10]$ monotone increasing in α .

- From first-order condition for q^*
- Invert to get α as a function of q
 - Think first price auction: bid increasing in valuation
 - From Myerson symmetric equilibrium, invert bids to get valuations
- Identification by monotonicity!

Estimation

- **Goal:** estimate α distribution from the Bayes-Nash equilibrium q
- **Challenge:** unknown α distribution, unknown q distribution
- **Resolution:** Guerre, Perrigne and Vuong “Optimal Nonparametric Estimation of First-Price Auctions” *Econometrica* 2000
 - Estimate unknown q distribution by empirical q distribution
 - Use first-order condition, invert, then estimate α from q
 - Stack up estimated α 's to construct distribution
- **GPV Nonparametric Estimation:** consistent, asymptotically efficient, etc
- **Are α distributions different across markets and incentive configurations?**

Estimating α by quality distribution

- Replace altruism distribution F by the equilibrium quality distribution G :

$$\alpha = \frac{2cqU'(p - cq^2) \int_0^{10} S(q; x) dG(x) - U(p - cq^2) \times \int_0^{10} bS(q; x)[1 - S(q; x)] dG(x)}{b \int_0^{10} S(q; x) dG(x) + bq \int_0^{10} bS(q; x)[1 - S(q; x)] dG(x)}$$

- G estimated by empirical quality distribution—GPV

The Experiment

- **Within-subject design**
 - Monopoly, Duopoly, Quadropoly
 - Price, cost, benefit; each binary
 - total of $3 \times 2 \times 2 \times 2 = 24$ games for each subject
- **When: sessions in October 2017, April 2018**
- **Where: University of Cologne**
- **Who: 361 subjects, most of them Cologne students**
 - Average age, 24 years; 55% female. Subjects of study: 131 in law and social sciences, 22 in medicine, 42 in arts and humanities, 49 in mathematics and natural sciences, 35 in theology, and 82 others, non-students, unavailable
- **What: played normal form games, exactly those above**

Time left [sec]:

Patient type 1

Capitation: 10

Quality	Costs	Profit	Patient benefit
0	0.00	10.00	0
1	0.10	9.90	1
2	0.40	9.60	2
3	0.90	9.10	3
4	1.60	8.40	4
5	2.50	7.50	5
6	3.60	6.40	6
7	4.90	5.10	7
8	6.40	3.60	8
9	8.10	1.90	9
10	10.00	0.00	10

 Your decision:

Time left [sec]:

Patient type 1

Capitation: 10

Quality	Costs	Profit	Patient benefit
0	0.00	10.00	0
1	0.10	9.90	1
2	0.40	9.60	2
3	0.90	9.10	3
4	1.60	8.40	4
5	2.50	7.50	5
6	3.60	6.40	6
7	4.90	5.10	7
8	6.40	3.60	8
9	8.10	1.90	9
10	10.00	0.00	10

	My Quality	Quality 2nd physician	
Quality	<input type="text"/>	<input type="text"/>	<input type="button" value="Calculate"/>
Number of patients			
Profit			
Patient benefit			

Your decision:

Time left [sec]:

Patient type 1
Capitation: 10

Quality	Costs	Profit	Patient benefit
0	0.00	10.00	0
1	0.10	9.90	1
2	0.40	9.60	2
3	0.90	9.10	3
4	1.60	8.40	4
5	2.50	7.50	5
6	3.60	6.40	6
7	4.90	5.10	7
8	6.40	3.60	8
9	8.10	1.90	9
10	10.00	0.00	10

	My Quality	Quality second physician	Quality third physician	Quality fourth physician	
Quality	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="text"/>	<input type="button" value="Calculate"/>
Number of patients					
Profit					
Patient benefit					

Remaining time [sec]:

Patient type 1

Capitation: **10**

Quality	Costs	Profit	Patient benefit
0	0.00	10.00	0
1	0.10	9.90	1
2	0.40	9.60	2
3	0.90	9.10	3
4	1.60	8.40	4
5	2.50	7.50	5
6	3.60	6.40	6
7	4.90	5.10	7
8	6.40	3.60	8
9	8.10	1.90	9
10	10.00	0.00	10

	My Quality	Quality second physician	
Quality	<input type="text" value="5"/>	<input type="text" value="4"/>	<input type="button" value="Calculate"/>
Number of patients	73	27	
Profit	547.50	226.80	
Patient benefit	365.00	108.00	

Your Decision:

Sessions

- Randomly assign subjects to 6 market sequences
 - (M-D-Q); (M-Q-D); (D-M-Q); (D-Q-M); (Q-M-D); (Q-D-M)
- Price-cost-benefit, or incentive, configurations order in all markets
 - 1st, ($p = 10$, $c = 0.1$, $b = 1$)
 - 2nd, ($p = 10$, $c = 0.075$, $b = 1$)
 - 3rd, ($p = 15$, $c = 0.1$, $b = 0.5$)
 - 4th, ($p = 15$, $c = 0.1$, $b = 1$)
 - 5th, ($p = 10$, $c = 0.1$, $b = 0.5$)
 - 6th, ($p = 10$, $c = 0.075$, $b = 0.5$)
 - 7th, ($p = 15$, $c = 0.075$, $b = 1$)
 - 8th, ($p = 15$, $c = 0.075$, $b = 0.5$)

Other details





- No real patients; quality benefits translate to donation to charity
- Subjects only informed about market on a “need-to-know” basis
- Subjects get aggregated information of actual demands, profits, and patient benefits
- Subjects’ profits and patient benefits: by “random choice” method in each market
- Control questions to test subjects’ comprehension
- Sessions averaged 90 minutes; subjects earned €14.20 (€18.20 including show-up fee)
- €2,923.60 donated to the Christoffel Blindenmission, in Masvingo, Zimbabwe; enough for 97 cataract surgeries





Estimation





- **Linear utility** $U(x) = x$
 - α : marginal rate of substitution between profit and patient benefit
- **CARA utility** $U(x) = 1 - \exp(-rx)$, set $r = 0.1$ (as robustness check)
- **Normalization:**
 - Recall 8 incentive configurations in 3 markets
 - For each incentive configuration, choose monopoly as origin
 - Find mean of estimated α , say α_i^M , $i =$ incentive configuration; M monopoly
 - Display $\alpha - \alpha_i^M$ for all i in all three markets
 - Measure α altruism as deviations from the monopoly mean





Linear Utility: means and standard deviations of normalized α





Incentive configurations	Monopoly		Duopoly		Quadropoly	
	mean	st. dev.	mean	st. dev.	mean	st. dev.
$(p = 10, c = 0.075, b = 0.5)$	0	0.898	-1.335	0.939	-1.579	0.766
$(p = 10, c = 0.075, b = 1)$	0	0.448	-0.812	0.612	-0.985	0.657
$(p = 10, c = 0.1, b = 0.5)$	0	1.117	-1.378	0.903	-2.233	1.710
$(p = 10, c = 0.1, b = 1)$	0	0.559	-0.882	0.725	-1.069	0.822
$(p = 15, c = 0.075, b = 0.5)$	0	1.028	-1.980	0.928	-2.382	0.980
$(p = 15, c = 0.075, b = 1)$	0	0.512	-1.244	0.767	-1.471	1.138
$(p = 15, c = 0.1, b = 0.5)$	0	1.308	-2.001	1.327	-2.428	1.147
$(p = 15, c = 0.1, b = 1)$	0	0.638	-1.207	0.827	-1.485	1.016

































Equilibrium qualities





- Three markets
- Eight incentive configurations



















Counterfactuals

- What would qualities look like if there were no altruism change?
- Impossible to get analytical formulas for Bayes-Nash equilibrium qualities
- Take estimates of altruism parameters in duopoly and quadropoly
 - Feed them into formulas for optimal qualities in monopoly
 - Counterfact qualities


Monopoly quality from Duopoly alpha
 $p=10, c=0.075, b=0.5$




Monopoly quality from Duopoly alpha
 $p=10, c=0.075, b=1$











Monopoly quality from Duopoly alpha
 $p=10, c=0.1, b=0.5$







Monopoly quality from Duopoly alpha
 $p=10, c=0.1, b=1$









Means and standard deviations of qualities

Incentive configurations	Monopoly		Duopoly		Quadropoly	
	mean	st. dev.	mean	st. dev.	mean	st. dev.
$(p = 10, c = 0.075, b = 0.5)$	4.17	2.99	7.75	1.58	8.26	1.40
$(p = 10, c = 0.075, b = 1)$	4.15	2.99	7.98	1.59	8.31	1.56
$(p = 10, c = 0.1, b = 0.5)$	3.79	2.79	6.94	1.35	7.34	1.34
$(p = 10, c = 0.1, b = 1)$	3.73	2.80	7.09	1.52	7.46	1.34
$(p = 15, c = 0.075, b = 0.5)$	4.82	3.43	8.82	1.53	9.09	1.32
$(p = 15, c = 0.075, b = 1)$	4.83	3.41	8.98	1.60	9.15	1.43
$(p = 15, c = 0.1, b = 0.5)$	4.51	3.27	8.19	1.63	8.55	1.47
$(p = 15, c = 0.1, b = 1)$	4.44	3.19	8.40	1.62	8.65	1.61

Parameter	Low parameter level (N=1,444, per market)		High parameter level (N=1,444, per market)		Relative difference
	Mean	st. dev.	Mean	st. dev.	
Price ($p = 10$ and $p = 15$)					
Monopoly	3.959	2.900	4.652	3.327	0.175
Duopoly	7.442	1.573	8.595	1.625	0.155
Quadropoly	7.841	1.479	8.862	1.484	0.130
Cost ($c = 0.075$ and $c = 0.1$)					
Monopoly	4.493	3.227	4.118	3.038	-0.083
Duopoly	8.380	1.660	7.657	1.662	-0.086
Quadropoly	8.704	1.489	8.000	1.564	-0.081
Patient benefit ($b = 0.5$ and $b = 1$)					
Monopoly	4.323	3.150	4.287	3.128	-0.008
Duopoly	7.925	1.668	8.112	1.726	0.024
Quadropoly	8.310	1.523	8.393	1.608	0.010

Duopoly	3.713*** (0.158)	3.713*** (0.158)		3.713*** (0.158)	3.545*** (0.157)
Quadropoly	4.046*** (0.157)	4.046*** (0.157)		4.046*** (0.157)	3.987*** (0.156)
High price (= 1 if $p_H = 15$)			0.955*** (0.0292)	0.955*** (0.0292)	0.693*** (0.0504)
High cost (= 1 if $c_H = 0.1$)			-0.601*** (0.0235)	-0.601*** (0.0235)	-0.375*** (0.0456)
High benefit (= 1 if $b_H = 1$)			0.0783*** (0.0238)	0.0783*** (0.0238)	-0.0360 (0.0429)
Duopoly \times High price					0.461*** (0.0659)
Quadropoly \times High price					0.328*** (0.0608)
Duopoly \times High cost					-0.348*** (0.0558)
Quadropoly \times High cost					-0.328*** (0.0545)
Duopoly \times High benefit					0.224*** (0.0560)
Quadropoly \times High benefit					0.119** (0.0551)
Market order and session dummies	No	Yes	Yes	Yes	Yes
Constant	4.305*** (0.155)	4.188*** (0.400)	6.558*** (0.378)	3.971*** (0.400)	4.047*** (0.399)
Observations	8,664	8,664	8,664	8,664	8,664
Subjects	361	361	361	361	361
R^2	0.399	0.407	0.046	0.445	0.447

Market orders and between-subject subsample

- Does it matter if subjects experience monopoly before duopoly, etc?
 - Results similar
- Use 1/3 of data to construct between-subject design
 - Take subjects' first market experience
 - Results similar

BMW (Byambadalai, Ma, and Wiesen) questioning the basics

-
- **Preferences-Markets-Incentives altogether, not independent**
- **Competition and incentives are like switches**
- **Why? Or should it be what or how?**
- **Cognitive demands?**
- **Reductionism: “Equity theory and fair inequality: A neuroeconomic study” by Cappelen, Proceedings of the National Academy of Science, 2014**